ArticlePloS one2011
Identification of antigens specific to non-tuberculous mycobacteria: the Mce family of proteins as a target of T cell immune responses.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Immunity AgainstVaccines · 2025Article
- Characterization of mycobacteria isolated from the Brazilian Atlantic Forest: a public health and bioprospection perspective.Frontiers in microbiology · 2025Article
- T-cell deficiency and hyperinflammatory monocyte responses associate withFrontiers in immunology · 2022Article
- Adaptive Immune Response toFrontiers in cellular and infection microbiology · 2022Article
- Article
- Molecular Cloning, Purification and Characterization of Mce1R of Mycobacterium tuberculosis.Molecular biotechnology · 2021Article
- Exploiting Pre-Existing CD4Journal of immunology (Baltimore, Md. : 1950) · 2020Article
- Article
- Nontuberculous Mycobacteria and Heterologous Immunity to Tuberculosis.The Journal of infectious diseases · 2019Review
- The complexities and challenges of preventing and treating nontuberculous mycobacterial diseases.PLoS neglected tropical diseases · 2019Review
- What Have We Learnt about BCG Vaccination in the Last 20 Years?Frontiers in immunology · 2017Review
- Immunological consequences of intragenus conservation of Mycobacterium tuberculosis T-cell epitopes.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Understanding BCG is the key to improving it.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2014Article
- Prime-boost approaches to tuberculosis vaccine development.Expert review of vaccines · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
The lack of an effective TB vaccine hinders current efforts in combating the TB pandemic. One theory as to why BCG is less protective in tropical countries is that exposure to non-tuberculous mycobacteria (NTM) reduces BCG efficacy. There are currently several new TB vaccines in clinical trials, and NTM exposure may also be relevant in this context. NTM exposure cannot be accurately evaluated in the absence of specific antigens; those which are known to be present in NTM and absent from M. tuberculosis and BCG. We therefore used a bioinformatic pipeline to define proteins which are present in common NTM and absent from the M. tuberculosis complex, using protein BLAST, TBLASTN and a short sequence protein BLAST to ensure the specificity of this process. We then assessed immune responses to these proteins, in healthy South Africans and in patients from the United Kingdom and United States with documented exposure to NTM. Low level responses were detected to a cluster of proteins from the mammalian cell entry family, and to a cluster of hypothetical proteins, using ex vivo ELISpot and a 6 day proliferation assay. These early findings may provide a basis for characterising exposure to NTM at a population level, which has applications in the field of TB vaccine design as well as in the development of diagnostic tests.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.